Cargando…

SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients

We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1(+) myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostendorf, Lennard, Dittert, Philipp, Biesen, Robert, Duchow, Ankelien, Stiglbauer, Victoria, Ruprecht, Klemens, Bellmann-Strobl, Judith, Seelow, Dominik, Stenzel, Werner, Niesner, Raluca A., Hauser, Anja E., Paul, Friedemann, Radbruch, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119413/
https://www.ncbi.nlm.nih.gov/pubmed/33986412
http://dx.doi.org/10.1038/s41598-021-89786-0
_version_ 1783691849640181760
author Ostendorf, Lennard
Dittert, Philipp
Biesen, Robert
Duchow, Ankelien
Stiglbauer, Victoria
Ruprecht, Klemens
Bellmann-Strobl, Judith
Seelow, Dominik
Stenzel, Werner
Niesner, Raluca A.
Hauser, Anja E.
Paul, Friedemann
Radbruch, Helena
author_facet Ostendorf, Lennard
Dittert, Philipp
Biesen, Robert
Duchow, Ankelien
Stiglbauer, Victoria
Ruprecht, Klemens
Bellmann-Strobl, Judith
Seelow, Dominik
Stenzel, Werner
Niesner, Raluca A.
Hauser, Anja E.
Paul, Friedemann
Radbruch, Helena
author_sort Ostendorf, Lennard
collection PubMed
description We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1(+) myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1(+) myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. In our cohort, SIGLEC1 expression on monocytes was—apart from those patients receiving interferon treatment—not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. SIGLEC1(+) myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. The presence of SIGLEC1(+) myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion.
format Online
Article
Text
id pubmed-8119413
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81194132021-05-14 SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients Ostendorf, Lennard Dittert, Philipp Biesen, Robert Duchow, Ankelien Stiglbauer, Victoria Ruprecht, Klemens Bellmann-Strobl, Judith Seelow, Dominik Stenzel, Werner Niesner, Raluca A. Hauser, Anja E. Paul, Friedemann Radbruch, Helena Sci Rep Article We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1(+) myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1(+) myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. In our cohort, SIGLEC1 expression on monocytes was—apart from those patients receiving interferon treatment—not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. SIGLEC1(+) myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. The presence of SIGLEC1(+) myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion. Nature Publishing Group UK 2021-05-13 /pmc/articles/PMC8119413/ /pubmed/33986412 http://dx.doi.org/10.1038/s41598-021-89786-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ostendorf, Lennard
Dittert, Philipp
Biesen, Robert
Duchow, Ankelien
Stiglbauer, Victoria
Ruprecht, Klemens
Bellmann-Strobl, Judith
Seelow, Dominik
Stenzel, Werner
Niesner, Raluca A.
Hauser, Anja E.
Paul, Friedemann
Radbruch, Helena
SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_full SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_fullStr SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_full_unstemmed SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_short SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_sort siglec1 (cd169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119413/
https://www.ncbi.nlm.nih.gov/pubmed/33986412
http://dx.doi.org/10.1038/s41598-021-89786-0
work_keys_str_mv AT ostendorflennard siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT dittertphilipp siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT biesenrobert siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT duchowankelien siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT stiglbauervictoria siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT ruprechtklemens siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT bellmannstrobljudith siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT seelowdominik siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT stenzelwerner siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT niesnerralucaa siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT hauseranjae siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT paulfriedemann siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
AT radbruchhelena siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients